Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival

Oncogene

Volumn 27, Issue 56, 2008, Pages 7106-7117

  Wang, Y ^a,b   Mikhailova, M ^c   Bose, S ^a   Pan, C X ^a,b   White, R W DeVere ^a   Ghosh, P M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Akt; Androgen independence; Apoptosis; mTOR; Raptor; Rictor

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; SIROLIMUS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

MAMMALIA; RAPTORES;

EID: 58149233953     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.318     Document Type: Article

References (30)

1. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW et al. (1999). Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91: 1869-1876.
2. Boehmer A, Anastasiadis AG, Feyerabend S, Nagele U, Kuczyk M, Schilling D et al. (2005). Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience. Anticancer Res 25: 4481-4486.
3. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS et al. (1994). A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369: 756-758.
4. Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR et al. (2006). Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 66: 10040-10047.
5. Cinar B, De Benedetti A, Freeman MR. (2005). Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res 65: 2547-2553.
6. Edwards J, Bartlett JM. (2005). The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int 95: 1320-1326.
7. Gao N, Zhang Z, Jiang BH, Shi X. (2003). Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310: 1124-1132.
8. Ghosh PM, Bedolla R, Mikhailova M, Kreisberg JI. (2002). RhoA-dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Czeta. Cancer Res 62: 2630-2636.
9. Ghosh PM, Ghosh-Choudhury N, Moyer ML, Mott GE, Thomas CA, Foster BA et al. (1999). Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 18: 4120-4130.
10. Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ et al. (2005). Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer 12: 119-134.
11. Ghosh PM, Mikhailova M, Bedolla R, Kreisberg JI. (2001). Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor. Am J Physiol Renal Physiol 280: F972-F979.
12. Gingras AC, Raught B, Sonenberg N. (2001). Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807-826.
13. Hartig PC, Bobseine KL, Britt BH, Cardon MC, Lambright CR, Wilson VS et al. (2002). Development of two androgen receptor assays using adenoviral transduction of MMTV-luc reporter and/or hAR for endocrine screening. Toxicol Sci 66: 82-90.
14. Hresko RC, Mueckler M. (2005). mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280: 40406-40416.
15. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A et al. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128.
16. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K et al. (2006). Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66: 1203-1212.
17. Lee CH, Inoki K, Guan KL. (2007). mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol 47: 443-467.
18. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY et al. (2003). Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 278: 50902-50907.
19. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ. (1999). Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 13: 376-384.
20. Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D et al. (2001). Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 276: 27462-27469.
21. Petrylak D. (2005). Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int 96(Suppl 2): 41-46.
22. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. (1994). RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78: 35-43.
23. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H et al. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302.
24. Sarbassov DD, Ali SM, Sabatini DM. (2005a). Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596-603.
25. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF et al (2006). Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168.
26. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005b). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
27. Sharef S, Jac J, Khan M, Amato R. (2006). Rapamycin for androgen-independent prostrate cancer (AIPC). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), pp 14584.
28. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. (2005). Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4: 1533-1540.
29. Tzatsos A, Kandror KV. (2006). Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26: 63-76.
30. Wu L, Birle DC, Tannock IF. (2005). Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65: 2825-2831.